Luspaterecpt before epoetin in low grade MDS patients.
Paradigm shift in rectal cancer therapy? Some may not need surgery, now some may not need radiotherapy.
Combination PARP with androgen blocker, regardless of HRR gene alterations showed benefit vs. androgen blocker alone.
Targeted therapy in NSCLC, FCS was part of this trial.
Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.
CAR-T for second line is better than standard of care, the question is: how about compared to BITE therapy? Future is exciting for those patients.
High burden prostate cancer patients benefit form androgen deprivation and Taxotere combination.
For our radiation oncology colleagues, any comments? For oligometastases, radiation therapy helps improve survival when added to systemic therapy.
The NADIM-II study looked at perioperative Nivo+chemo vs. chemo alone in stIIIA – stIIIB NSCLC. High pCR rates with chemoIO are again seen, as in the Checkmate 816 and NADIM-I study, they were even higher in this cohort (37%), suggesting higher-stage patients derive the biggest benefit from neoadjuvant chemoIO. Pretty impressive results, however, I still must point out that this was a phase II study with a small sample size, OS benefits have not been demonstrated and this has yet to make it on to NCCN.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
